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Abstract
Background:  Activation of the phosphatidylinositol 3-kinase (PI3K) through mutational
inactivation of PTEN tumour suppressor gene is common in diverse cancer types, but rarely
reported in gastric cancer. Recently, mutations in PIK3CA, which encodes the p110α  catalytic
subunit of PI3K, have been identified in various human cancers, including 3 of 12 gastric cancers.
Eighty percent of these reported mutations clustered within 2 regions involving the helical and
kinase domains. In vitro study on one of the "hot-spot" mutants has demonstrated it as an activating
mutation.
Methods: Based on these data, we initiated PIK3CA mutation screening in 94 human gastric cancers
by direct sequencing of the gene regions in which 80% of all the known PIK3CA mutations were
found. We also examined PIK3CA expression level by extracting data from the previous large-scale
gene expression profiling study. Using Significance Analysis of Microarrays (SAM), we further
searched for genes that show correlating expression with PIK3CA.
Results: We have identified PIK3CA mutations in 4 cases (4.3%), all involving the previously
reported hotspots. Among these 4 cases, 3 tumours demonstrated microsatellite instability and 2
tumours harboured concurrent KRAS mutation. Data extracted from microarray studies showed
an increased expression of PIK3CA in gastric cancers when compared with the non-neoplastic
gastric mucosae (p < 0.001). SAM further identified 2910 genes whose expression levels were
positively associated with that of PIK3CA.
Conclusion: Our data suggested that activation of the PI3K signalling pathway in gastric cancer
may be achieved through up-regulation or mutation of PIK3CA, in which the latter may be a
consequence of mismatch repair deficiency.
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Background
The phosphatidylinositol 3-kinase (PI3K)-AKT signalling
pathway is involved in the regulation of diverse cellular
processes, including cell growth, survival and motility.
Abnormal activation of this pathway is frequently
observed in various cancer types, leading to aberrant cell
cycle progression, altered adhesion and motility, inhibi-
tion of apoptosis and induction of angiogenesis [1]. It has
been previously reported that genetic alterations involv-
ing various members along this signalling pathway could
lead to its activation in cancer. These include mutation,
allelic loss or promoter methylation of the negative regu-
lator PTEN [2]; or alternatively, chromosomal amplifica-
tion or over-expression of the positive regulators PIK3CA
[3-5] and the various AKT  kinases [6,7]. Furthermore,
changes in other related pathways that are commonly
altered in cancer, such as those involved in growth factor
stimulation via the G-protein-coupled receptors or
through direct interaction with the activated form of small
GTPase RAS, can also lead to PI3K-AKT pathway activa-
tion [8]. Activation of this pathway results in the phos-
phorylation of AKT at Thr-308/309 and Ser-473/474.
These phosphorylated forms of AKT proteins have been
detected by Western blot or immunohistochemistry in
various cancer types, suggesting the frequent activation of
PI3K-AKT pathway in the carcinogenic process [7,9].
Although genetic changes along the PI3K-AKT pathway
have been repeatedly documented in brain, ovarian,
endometrial, breast, prostate and thyroid cancers [1,2],
reports on its mechanism of activation in gastric cancer
are limited. Gastric cancer is the second most common
cancer worldwide but its molecular basis of tumourigene-
sis is still poorly understood. Previous immunohisto-
chemical study has demonstrated the presence of the
phosphorylated form of AKT in 78% of gastric cancer [10],
suggesting that activation of this pathway may also be
common in gastric cancer. Though loss of heterozygosity
(LOH) involving the PTEN locus has been demonstrated
in 47% of gastric cancer in a recent study, mutation or pro-
moter methylation was absent even in cases with LOH
[11]. Thus data from this study could not support the two-
hit inactivation of PTEN in gastric cancer, while the bio-
logical significance of PTEN haploinsufficiency remains
controversial. Alternatively, amplification of AKT1  has
been reported in a single case of gastric cancer [12], and
amplification of PIK3CA associated with elevated mRNA
levels has been found in 36% of gastric cancer [11]. More
recently, Samuels et al. screened a diverse spectrum of
human cancers for mutation in 16 PI3K or PI3K-like genes
and found a high frequency of somatic mutation in
PIK3CA, which encodes the p110α  catalytic subunit.
Major screening in colorectal cancer (CRC) identified
PIK3CA mutations in 74 out of 234 (32%) cases, while
mutations were also noted in 3 out of 12 (25%) gastric
cancers. Reported mutations were mostly of missense
type, and clustered within 2 regions in the helical and
kinase domains. Expression of a "hot-spot" mutant,
H1047R, conferred a significant up-regulation of lipid
kinase activity of PIK3CA, suggesting it as an activating
mutation [13]. In this study, we have examined a series of
94 human gastric adenocarcinomas for PIK3CA mutation.
We have also examined PIK3CA  expression level by
extracting data from a large-scale gene expression profil-
ing study previously performed for these cases [14,15].
Using SAM, genes with significant correlating expression
with PIK3CA have also been identified.
Methods
Patient samples preparation
DNA samples used for sequencing were prepared from
frozen tumour and non-tumour gastric mucosae from 94
gastric cancer patients who underwent gastrectomy in the
Department of Surgery, Queen Mary Hospital, The Uni-
versity of Hong Kong, as previously described [16]. Major-
ity of the frozen samples (n = 81) showed tumour
component of over 70%, whereas in 13 cases a lower pro-
portion between 50 to 70% was accepted due to the
tumours' inherent diffuse infiltrative nature with entrap-
ment of non-neoplastic components. Analysis for micros-
atellite instability (MSI), BRAF and KRAS mutation have
been performed and reported previously [16]. RNA prep-
aration and gene expression profiling using a cDNA
microarray containing 44,500 cDNA clones, representing
around 30,300 unique genes, has been performed and
reported in 90 of these tumours in comparison to 22 non-
tumour gastric mucosae [14,15]. This study was approved
by the Ethics Committee of the University of Hong Kong.
Mutational screening
Mutation screening of PIK3CA was performed for exons 9
and 20, covering the mutational hotspots; and for exon
18, from which a mutation was found in a gastric cancer.
Mutations in these 3 exons constituted 80% of all PIK3CA
mutations detected in the previous study [13]. PIK3CA
intron-specific external amplification primers and inter-
nal sequencing primers were designed according to the
previous study [13] with some modifications [see Addi-
tional file 1]. In particular, primers for exon 9 have been
modified to avoid amplification of homologous
sequences located in other chromosomes. PCR products
were generated using the external primers and directly
sequenced using the internal primers with the
DYEnamic™ ET Terminator Cycle Sequencing Kit (Amer-
sham Biosciences, Freiburg, Germany) according to the
manufacturer's instruction. Electrophoresis was per-
formed in the ABI Prism® 3700 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). For each exon, PCR
products were generated from 2 independent PCR reac-
tions for sequencing of the forward and reverse strands.BMC Cancer 2005, 5:29 http://www.biomedcentral.com/1471-2407/5/29
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For exon 9, 2 independent PCR followed by sequencing of
the forward strand were performed. Analysis of the chro-
matograms was performed using the mutation analysis
software Mutation Explorer™ (SoftGenetics, State College,
PA, USA).
Extraction of expression data and statistical analysis
Gene expression data were extracted from the microarray
database containing 126 samples (90 gastric cancers, 14
lymph node metastasis and 22 non-tumour gastric
mucosae) based on a 3-fold signal above background
ratio for either channel and with 80% good data [14].
Gene expression data from 20,336 cDNA clones satisfied
this selection criteria and were extracted, which included
a cDNA clone corresponding to PIK3CA (IMAGE clone
number 345430, GenBank accession no. W72473).
Expression data for PIK3CA was extracted and the differ-
ences in expression levels between tumour and non-
tumour tissues were examined using the Student's t-Test.
SAM was performed to identify genes with significant cor-
relating expression with PIK3CA [17]. The missing values
in the dataset were estimated by a K-nearest neighbours
impute algorithm using 10 nearest neighbour [18] fol-
lowed by 5000 permutations in the SAM analysis.
Results
Among the 94 gastric adenocarcinoma analysed, we have
detected  PIK3CA  mutation in 4 cases. Two cases har-
boured the mutation A3140G (H1047R) in exon 20, and
the other 2 cases with mutations G1624A (E542K) and
G1633A (E545K) in exon 9. Representative sequence
chromatograms are shown in figure 1. All four mutations
were absent in the corresponding non-neoplastic
mucosae and thus were confirmed as somatic mutations.
Though the overall mutation frequency (4.3%) was lower
than that of the previous study, the nature of the 4 muta-
tions found were consistent with those identified at the
reported hotspots. In particular, the H1047R mutation
has been reported in 2 gastric cancers and 15 colorectal
cancers [13]. While the E542K and the E545K mutations
were not found in gastric cancer in the previous series, a
large number of colorectal tumours did harbour these 2
mutations.
PIK3CA mutation spectrum and their corresponding clin-
ico-pathological features were listed in Table 1. We noted
a higher tendency of high-level MSI in gastric cancers with
PIK3CA mutations (3 in 4, 75%) than in those without
(18 in 90, 20%). Moreover, though the overall incidence
of KRAS mutation in the studied population was low (8 in
94), 2 of the 4 gastric cancers with PIK3CA mutation also
harboured a KRAS mutation.
Since over-expression of PIK3CA has been reported in gas-
tric cancer [11], we have also extracted PIK3CA expression
data from our previous cDNA microarray study of these
cases [14,15]. We have confirmed that expression level of
PIK3CA was significantly higher in gastric cancers (n = 87,
mean = 0.099, SD = 0.428) when compared with non-
neoplastic gastric mucosae (n = 22, mean = -0.418, SD =
0.426; Student's t-Test, p < 0.001). Using PIK3CA expres-
sion level as a continuous variable for SAM analysis [17],
we found 2910 cDNA clones (corresponding to about
2546 unique genes) whose expression associated posi-
tively with PIK3CA expression (median number of false
significant = 0.372, Delta = 1.107) [see Additional file 2].
Interestingly, no gene was found to be negatively associ-
ated with PIK3CA expression.
Discussion
In this study, we have reported the presence of PIK3CA
gene mutation in 4.3% of gastric cancer. A high tendency
(3 in 4) of mismatch repair deficiency was noted in cases
harbouring PIK3CA mutation. Though the small number
of PIK3CA mutations in our study may not justify statisti-
cal claim of significance; suggestion of such, despite of its
not being mentioned by the authors, can be found from a
previous study in CRC by Samuels et al.. From their study
of 33 MSI and 201 microsatellite stable (MSS) CRC cases,
PIK3CA mutation was present in 48% of the MSI tumours,
Representative sequence chromatogram Figure 1
Representative sequence chromatogram. (a) Sequence 
chromatogram from a case of gastric cancer with H1047R 
(A3140G) mutation within exon 20 of PIK3CA. Site of muta-
tion is denoted by the red arrow. (b) Sequence chromato-
gram of the corresponding normal mucosa from the same 
case showing the absence of mutation (red arrow), and thus 
confirming the somatic nature of the mutation.BMC Cancer 2005, 5:29 http://www.biomedcentral.com/1471-2407/5/29
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but only in 29% of the MSS tumours. A significant associ-
ation would have been revealed if statistical analysis had
been applied (Fisher's exact test, p = 0.014) [13]. Gastroin-
testinal tract cancers with MSI are known to have a differ-
ent molecular pathway of tumour evolution compared
with their MSS counterparts [19,20]. This can be attrib-
uted to their propensity for frameshift mutations in repeat
sequences, resulting in selective disruption of genes with
such sequences within their coding regions. With 2 poly-
adenine tracts within its coding region, PTEN can be inac-
tivated through frameshift mutations in MSI CRC, result-
ing in the selective targeting of the PI3K-AKT signalling
pathway [21,22]. It is also known that mismatch repair
deficiency would lead to an elevated rate of missense
mutation due to impaired single nucleotide mismatch
repair [23]. Thus, the observed higher incidence of
PIK3CA missense mutation in MSI colorectal and gastric
cancers suggests yet another mechanism for the activation
of the PI3K-AKT signalling pathway through mismatch
repair deficiency.
Our data also showed a higher tendency of KRAS muta-
tion in cases with PIK3CA mutations (2 in 4) than in those
without (6 in 90). Yet again due to the low incidence of
both mutations in our samples, statistical significance
may not be claimed. In the study by Samuels et al., some
of the colorectal tumours with PIK3CA mutation also har-
boured KRAS or BRAF mutation [13]. The PI3K-AKT path-
way is known to have a close association with the RAS-
MEKK signalling pathway [8]. Constitutively active RAS
can interact with the catalytic subunit of PI3K and lead to
its activation. Ras-dependent PI3K activation contributes
to the transforming phenotype by mediating anchorage-
independent growth, cytoskeletal reorganisation and
apoptosis evasion. It has been observed that genes
involved in the same signalling pathway may manifest
mutations in cancer cells in a mutually exclusive manner,
presumably due to the lack of selective growth advantage
in having a second hit in the already altered pathway. A
prominent example is the mutually exclusive occurrence
of the BRAF hotspot mutation (V600E) and KRAS muta-
tions in colorectal cancer [24,25]. However, there exist
other examples of alterations in multiple components of
the same signalling pathway that may lead to a multi-level
modulation of its activity. For example, non-V600E BRAF
mutations tend to occur together with KRAS mutations
[26], and inactivation of the secreted frizzled-related pro-
teins (antagonists of WNT) by promoter methylation fre-
quently coincides with mutations in the Adenomatous
Polyposis Coli gene to achieve multi-level activation of
the WNT signalling pathway in colorectal cancers [27].
Whether PIK3CA functions independently from RAS, or
acts synergistically with RAS to produce additive effects on
the activation of the same pathway awaits further
clarification.
By extracting data from microarray, we have confirmed
the up-regulation of PIK3CA expression in gastric cancer
tissues compared with the non-neoplastic gastric mucosae
and identified a large number of genes that showed a sig-
nificant positive correlation in expression level with
PIK3CA. These genes participate in diverse cellular proc-
esses with 177 as putative cell cycle-regulated genes [28]
and 126 mapped to genes with known functions in cell
cycle regulation, cell proliferation or DNA replication [see
Additional file 2]. While some of these genes maybe
induced by PIK3CA, others maybe co-ordinately regulated
by common upstream signals. Expression data set at one
point was limited in differentiating the above cause and
consequence, yet it certainly revealed the complexity of
the carcinogenic process and the intricate relationship of
PIK3CA signalling with other cellular processes.
Contrary to our expectation, the incidence of PIK3CA
mutation found in the current study (4%) is much lower
compared with that observed by Samuel et al. (25%) [13].
The reason for discrepancy may simply be a result of sam-
ple bias as the previous study involved only a small
number of gastric cancers (n = 12). However, ethnic differ-
ences can also be another possibility. The diverse patho-
Table 1: Spectrum of PIK3CA mutations in gastric adenocarcinoma
Case Nucleotide 
Substitutiona
Amino acid 
change
Age Sex MSI Statusb,c KRAS Mutationc Tumour site Tumour type IMd
28 A3140G H1047R 37 M Stable - Body Intestinal 0
100 G1633A E545K 79 F High - Antrum Intestinal 1
240 G1624A E542K 74 M High G12D Antrum Intestinal 1
310 A3140G H1047R 72 F High G13D Antrum Intestinal 1
aNucleotide change at the position within coding sequence, where position 1 corresponds to the first position of the start codon
bHigh, high level of MSI; Stable, microsatellite stable
cAnalysis of KRAS mutations have been performed and reported previously [16]
dIM, the presence of intestinal metaplasia at tumour edge; 1, present; 0, absentBMC Cancer 2005, 5:29 http://www.biomedcentral.com/1471-2407/5/29
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logical spectrum and aetiological factors of gastric cancers
in different geographical locations may be paralleled by
differences in molecular pathway of tumour develop-
ment. Since our current study is only based on a Chinese
population with an intermediate gastric cancer incidence,
further studies involving patients from different ethnic
groups will be able to address this possibility.
Conclusion
Large-scale screening of gastric adenocarcinomas for
PIK3CA  mutations revealed a mutation incidence of
4.3%. Increased PIK3CA expression level was observed in
gastric tumours compared with non-neoplastic mucosae.
This increase in PIK3CA level was associated with the ele-
vated expression of a large number of genes, which may
constitute the upstream regulators or downstream targets
of PIK3CA along the PI3K signalling pathway.
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